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Key points 
Increased FOXO1 is oncogenic in human CD34+ cells and promotes pre-leukemia transition. 
FOXO1 is required by AML1-ETO pre-leukemia cells for the activation of a stem cell molecular program. 
Abstract 
Understanding and blocking the self-renewal pathway of pre-leukemia stem cells could prevent acute 
myeloid leukemia (AML) relapse. In this study we show that increased FOXO1 represents a critical 
mechanism driving aberrant self-renewal in pre-leukemic cells expressing the t(8;21)-associated oncogene 
AML1-ETO (AE). Though generally considered as a tumor suppressor, FOXO1 is consistently 
upregulated in t(8;21) AML. Expression of FOXO1 in human CD34+ cells promotes a pre-leukemic state 
with enhanced self-renewal and dysregulated differentiation. The DNA binding domain of FOXO1 is 
essential for these functions. FOXO1 activates a stem cell molecular signature which is also present in AE 
pre-leukemia cells and preserved in t(8;21) patient samples. Genome-wide binding studies show that AE 
and FOXO1 share the majority of their binding sites, whereby FOXO1 binds to multiple crucial self-
renewal genes and is required for their activation. In agreement with this observation, genetic and 
pharmacological ablation of FOXO1 inhibited the long-term proliferation and clonogenicity of AE cells 
as well as t(8;21) AML cell lines. Targeting of FOXO1 therefore provides a potential therapeutic strategy 
for elimination of stem cells at both pre-leukemic and leukemic stages. 
 
Introduction 
Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy. Leukemogenesis is a 
hierarchical process, whereby an initiating mutation drives the development of pre-leukemic stem cells 
that evolve over time to overt disease through additional cooperating mutations.1 Pre-leukemic stem cells 
can survive chemotherapy and serve as a potential reservoir of disease relapse.2,3 The translocation at 
chromosome t(8;21) generating the AML1-ETO (RUNX1-RUNX1T1; AE) fusion protein is one of the 
most frequent initiating mutations, accounting for ~10% of total AML.4 Although t(8;21) AML has a 
comparatively good prognosis and most patients enter remission, approximately half of the patients 
relapse and only a 60% overall survival is achieved after five years.5 Pre-leukemic stem cells are evident 
in this AML subtype, as cells positive for AE can be detected long before disease onset or after complete 
remission.6-8 Thus, disrupting the self-renewal program of malignant stem cells will provide therapeutic 
opportunities for preventing disease relapse. 
We and others have shown that expression of AE in human CD34+ hematopoietic stem and progenitor 
cells (HSPCs) causes dysregulated differentiation and increased self-renewal of cells but without inducing 
AML,9,10 serving as an ideal model to study the pre-leukemic stage of t(8;21) AML (AE cells). Until now, 
the mechanism how AE programs progenitor cells into pre-leukemia with aberrant self-renewal has not 
been completely understood. 
The FOXO transcription factors include FOXO1, FOXO3, FOXO4 and FOXO6. Except for FOXO6 
which is expressed predominantly in the brain, all other FOXOs are ubiquitously expressed and act as 
essential regulators controlling oxidative stress and metabolic homeostasis,11 which is critical in 
hematopoietic stem cell (HSC) maintenance.12-14 Due to their capacity to arrest the cell cycle and activate 
apoptosis, FOXOs are well known tumor suppressors.15 However, the precise function of FOXOs in AML 
is unclear. The inactivation of FOXO3 in AML was reported, and restoring its activity impaired cell 
growth.16 On the other hand, in line with its critical role in HSC maintenance,17 FOXO3 was found to be 
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important for maintaining AML stem cells, although the molecular mechanism was not defined.18 It is 
therefore unclear whether FOXOs serve as tumor suppressors, as oncogenes or as stem cell maintenance 
genes.   
Different FOXO family members may have non-redundant functions.19 For instance, an HSC defect has 
been observed only in Foxo3- but not Foxo1-deficient mice.12 However, the role of FOXO1 in pre-
leukemia stem cells has not been explored. Here, we show FOXO1 can function as an oncogene whose 
upregulation promotes self-renewal and blocks the differentiation of human CD34+ HSPCs. In AE pre-
leukemic cells, this oncogenic function is required for the activation of a self-renewal program. Our 
results demonstrate a new function of FOXO1 in AML pathogenesis, strengthen our understanding of the 
mechanisms that mediate the aberrant self-renewal of pre-leukemia stem cells and reveal therapeutic 
strategies for their elimination.  
Methods 
Plasmids and reagents 
MSCV-IRES-GFP(MIG) and MSCV-AE-IRES-GFP retroviral vector was as described.20 pSIN-
TREtight-DsRED-IRES(tTRi) and MSCV-GFP-IRES-tTA retroviral vectors were generously provided 
by Dr. Johannes Zuber. Insertion of AE was subcloned into tTRi to build an AE-tet-off system. pSG5L-
FOXO1-WT and pBabe- puro-FOXO1 DB vectors were obtained from Addgene (#10693 and #10695). 
Insertions of FOXO1 WT and FOXO1 DB were then subcloned into MIG. Lentiviral vector MISSION 
pLKO.1-shRNA-puro constructs targeting human FOXO1 (TRCN0000039578, sh-1) and non-target 
shRNA control (shNT-1) were obtained from Sigma, the puromycin-resistant gene in the constructs was 
replaced with Venus marker. GIPZ lentiviral shRNA targeting FOXO1 (V3LHS_405827, sh-2) and non-
silencing control (shNT-2) were obtained from Open Biosystems, the shRNA insertions were subcloned 
into SF-LV-shRNA-EGFP lentiviral vector, a gift from Dr. K. Lenhard Rudolph. FOXO1 inhibitor 
AS1842856 was from Millipore (344355), dissolved in DMSO.  
Cells and culture 
Human umbilical cord blood cells (CB) were obtained by the Translational Trials Support Laboratory at 
CCHMC under institution-approved protocol. CD34+ cells were enriched using CD34+ selection kit 
(Miltenyi). AE pre-leukemic cells were established as described.10 AE cells and MIG/FOXO1- transduced 
CD34+ cells were cultured in IMDM with 20% BIT Serum Substitute (Stemcell Technologies #9500), 
supplemented with 10 ng/mL SCF, IL-3, IL-6, FLT3L, and TPO. Kasumi-1 and SKNO-1 cells were 
obtained from DSMZ, and cultured in RPMI 1640 with 20% fetal bovine serum (FBS) or RPMI 1640 
with 10% FBS plus 10 ng/mL GM-CSF, respectively. 
Methylcellulose colony-forming assays 
Assays were performed in MethoCult H4100 medium (Stemcell Technologies) supplemented with 20% 
BIT, 50 uM b-Mercaptoethanol, 2 mM L-glutamine, 100 U/mL penicillin/streptomycin, and the human 
cytokines Erythropoietin (6 U/mL), Granulocyte Colony Stimulating Factor (10 ng/mL), IL-6(20 ng/mL), 
IL-3 (20 ng/mL), and SCF (20 ng/mL). Colonies were scored at day 14, and then the cells were collected 
for replating. Some experiments were performed by using MethoCult Express medium (Stemcell 
Technologies), colonies were scored at day 7-10. 
Xenograft transplantation 
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Transplantation was performed on NOD/SCID/IL2RG-/- immunodeficient mice with transgenic 
expression of human SCF, granulocyte–macrophage colony-stimulating factor and IL-3(NSGS). 6- to 8-
week-old mice were conditioned with 30mg/kg busulphan (Sigma) through intraperitoneal injection 24 h 
before transplantation. For shRNA knockdown experiment, 5x105 transduced cells were transplanted to 
each mouse via tail vein. For FOXO1 overexpression experiment, 1x105 cells were transplanted through 
intrafemoral injection immediately after transduction. Bone marrow was aspirated for flow cytometry at 
indicated time. All experiments were performed in accordance with CCHMC institutional guidelines. 
RNA sequencing 
Three different units of CD34+ CB cells were transduced with MIG, AE, FOXO1 WT and FOXO1 DB. 
RNA was collected from sorted GFP+CD11b- cells 5 days after transduction using RNeasy Mini Kit 
(Qiagen). The integrity of RNA was analyzed by Bioanalyzer (Agilent). 1 ug total RNA was used for 
poly(A) RNA selection, followed by cDNA synthesis using PrepX mRNA Library kit (WaferGen) and 
Apollo 324 NGS automatic library prep system. Sample-specific index was added to the adaptor-ligated 
cDNA by PCR with index-specific primers for 13 cycles. The cluster generation of indexed libraries was 
carried out on cBot system (Illumina) using Illumina’s TruSeq SR Cluster kit v3, and then sequenced on 
Illumina HiSeq system using TruSeq SBS kit to generate single-end 50 cycle reads. 20-50 million reads 
were generated for each sample. More details about the data analyses can be found in supplemental 
Methods. 
Chromatin immunoprecipitation 
ChIP-Seq assays in AE cells were performed as previously described.21 More details about the protocol 
and the data analyses can be found in supplemental Methods. 
Data Access 
RNASeq and ChIP-Seq data have been deposited in GEO as GSE81084 and GSE80773.  
 
Results 
FOXO1 is upregulated in AE leukemia and pre-leukemia cells 
To identify critical regulators of self-renewal in AE AML, we examined an AML patient dataset 
published by Ross et al 22 for stem cell related genes that are significantly upregulated in t(8;21) AML 
cells compared to other AML subtypes. FOXO1 was one such gene (Figure 1A and supplemental Figure 
1A), a result which was further validated in additional datasets (supplemental Figure 1B). Expression of 
other FOXO family members did not differ significantly between t(8;21) and other AML subtypes 
(supplemental Figure 1C). We confirmed the upregulation of FOXO1 protein in t(8;21) AML primary 
patient samples compared to cytogenetically normal AML samples (Figure 1B). Increased FOXO1 
transcript and protein levels were also evident in AE pre-leukemia cells compared to control vector (MIT) 
transduced CD34+ HSPCs (Figures 1C-D), at levels similar to those in t(8;21) cell lines (Kasumi-1 and 
SKNO-1) and primary patient samples (supplemental Figure 1D-E). In contrast, AE did not elicit 
upregulation of other FOXOs in the same cells (supplemental Figure 1F).  The transcriptional activity of 
FOXOs is dependent on their nuclear localization,	 as	 they can be inactivated in AML cells by nuclear 
export.16 Cellular fractionation and immunoblot analysis showed that FOXO1 had a primarily nuclear 
distribution in AE cells and Kasumi-1 cells (Figure 1E and supplemental Figure 1G). Immunostaining 
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confirmed this finding, suggesting that FOXO1 is active in AE pre-leukemic and leukemic cells (Figure 
1F). 
To test whether FOXO1 is a downstream target of AE we developed a conditional (tet-off) AE expression 
system, and found that the expression of FOXO1 was highly dependent on continued expression of AE 
(Figure 2A-B). Similarly, when analyzing our previous RNA-seq study,21,23 we found that depletion of 
AE in Kasumi-1 cells led to a decrease of FOXO1 transcripts (Figure 2C-D). Chromatin 
immunoprecipitation-sequencing (ChIP-seq) analysis in Kasumi-1 cells21,23 showed that AE bound to the 
FOXO1 gene locus, where multiple RUNX1 binding motifs were identified (Figure 2E). We validated 
this binding using the anti-HA antibody to ChIP the epitope-tagged AE protein in AE cells (Figure 2F). 
These results suggest that FOXO1 could be a direct transcriptional target of AE.  
FOXO1 is required to sustain the growth of AE cells  
To investigate the function of FOXO1 in AE pre-leukemia cells, we knocked down FOXO1 using two 
independent pairs of shRNAs. AE cells with FOXO1 depletion displayed slightly increased apoptosis and 
reduced cell cycle progression compared to non-targeting shRNA (shNT) transduced cells (supplemental 
Figure 2A-B), although the differentiation status of the cells was not altered as indicated by CD11b 
expression (data not shown). FOXO1 knockdown impaired growth in liquid culture and clonogenicity of 
AE cells in a methylcellulose assay (Figure 3A-B). Additionally, FOXO1-depleted AE cells showed a 
reduced long-term engraftment capacity in immunodeficient mice, as the Venus+ fraction in engrafted 
human cells was reduced at week 9 post transplantation, and continuously decreased at later time points  
(Figure 3C and supplemental Figure 2C). These results suggest that FOXO1 does not act as a tumor 
suppressor, instead, FOXO1 ablation impairs the self-renewal of AE pre-leukemia cells both in vitro and 
in vivo. In addition, depletion of FOXO1 inhibited cell growth and colony formation of t(8;21) AML cell 
lines (supplemental Figure 2D-E), indicating that FOXO1 is also critical for leukemia maintenance. To 
further test this notion, we transduced shRNAs into an AE overt leukemic clone that spontaneously 
evolved from pre-leukemia cells,24 and evaluated its leukemogenicity in immunodeficient mice. The 
majority of mice receiving shNT-transduced cells succumbed to disease between 60-80 days after 
transplantation as expected. In contrast, recipients of FOXO1-depleted AE leukemia cells survived much 
longer (Figure 3D). Bone marrow examination showed that the cells with FOXO1 knockdown displayed a 
much lower engraftment level compared to shNT-transduced cells at a time-point when the latter were 
already showing overt disease (supplemental Figure 2F).        
We also evaluated FOXO1’s function using a FOXO1-specific inhibitor.25 Inhibitor treatment 
dramatically reduced the growth of AE pre-leukemia cells as well as of t(8;21) cell lines (Figure 3E and 
supplemental Figure 2G), partially by inducing apoptosis and blocking the cell cycle (supplemental 
Figure 2H-I). By contrast, the inhibitor showed only minimal effects on the growth of normal human 
CD34+ HSPCs, with an IC50 10 times higher than those of AE-expressed cells (Figure 3E-F). Consistent 
with the observation in liquid culture, the colony-forming potential of normal CD34+ HSPCs was 
unaffected by the inhibitor. However, the clonogenic activity of AE pre-leukemia cells and AML cell 
lines was impaired upon FOXO inhibition (Figure 3G-H). Importantly, the inhibitor also displayed 
efficacy on primary cells from t(8;21) AML patients, impeding their colony formation as well (Figure 3I). 
These findings are in accordance with data showing that Foxo1 knockout mice do not present with 
hematopoietic defects,12 demonstrating that FOXO1 is specifically required in AE pre-leukemia and 
leukemia cells.  
Increased FOXO1 has oncogenic activity in human CD34+ cells 
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The increase in FOXO1 upon AE expression in normal CD34+HSPCs suggested that FOXO1 could play 
a direct role in AE pathogenesis. To test this hypothesis, we transduced CD34+ HSPCs with a retrovirus 
expressing wild-type FOXO1 (FOXO1 WT) or only GFP (MIG) as control. To determine whether a 
transforming ability of FOXO1 relied on its DNA-binding activity, we also used a FOXO1 mutant unable 
to bind DNA (FOXO1 DB). FOXO1 WT promoted long-term proliferation of HSPCs in liquid culture, 
while control and FOXO1 DB cells grew for only a limited period (Figure 4A). Immunophenotyping and 
morphological analyses showed that FOXO1 WT cells retained an immature morphology with very little 
CD11b expression while control and FOXO DB cells underwent terminal myeloid differentiation (Figures 
4B-C). In methylcellulose clonogenic assays, FOXO1 WT cells gave rise to significantly more myeloid 
colonies with a dramatic loss of erythroid colonies when compared to MIG and FOXO1 DB cells (Figure 
4D). In addition, FOXO1 WT cells generated substantially more colonies in both secondary and tertiary 
re-platings, in striking contrast to control cells, where re-plating activity was limited (Figure 4E). All 
these effects are similar to the phenotype elicited upon AE expression.10  
To investigate the effect of FOXO1 expression in vivo, we transplanted transduced HSPCs into 
immunodeficient mice. Twelve weeks after transplantation, the proportion of GFP+ cells within human 
engraftment was measured. Consistent with our previous observation,26 control MIG cells did not 
maintain long-term engraftment in vivo and thus the percentage of engrafted human cells expressing GFP 
decreased over time. FOXO DB cells showed a similar loss in vivo, but with FOXO1 WT cells, the 
fraction of transduced cells was maintained (Figure 4F). However, as seen for AE cells, FOXO1 WT cells 
were unable to initiate AML. Taken together, these data indicate that enforced expression of FOXO1 in 
normal CD34+ HSPCs enhances stem cell function and disrupts differentiation, thus initiating a pre-
leukemic phenotype that resembles that of AE cells and highlighting an oncogenic function of FOXO1. 
Increased FOXO1 elicits a gene expression signature shared with AE expressing cells 
The transcriptional targets of FOXOs in normal HSCs and leukemia stem cells are poorly explored. To 
gain a better understanding of the underlying gene network accounting for FOXO1’s oncogenic role, we 
performed RNA-seq analysis on CD34+ HSPCs transduced with AE, FOXO1 WT, FOXO1 DB or MIG 
on day 5 post transduction. Hierarchical clustering analysis showed that gene expression patterns from 
FOXO1 DB and MIG cells clustered together, indicating that the expression of FOXO1 DB does not have 
a major impact on gene expression and thus was non-functional in this context. In contrast, gene 
expression patterns from AE and FOXO1 WT cells clustered separately from the control cells (Figure 5A 
and supplemental Table 1). More strikingly, a significant portion of the AE gene expression signature was 
also present in FOXO1 cells (Figure 5A and “Core gene” in supplemental Table 1). Pathway enrichment 
analysis on genes activated by FOXO1 compared to control cells showed a significant enrichment of 
published gene signatures characterizing AE pre-leukemia and leukemia. In addition, HSC signature 
genes were also significantly enriched (Figure 5B). These results suggest that FOXO1 regulates a core 
network associating with HSC function that is critical for AE mediated pre-leukemia stem cell 
programming. Accordingly, the FOXO1-activating gene signature was overrepresented in t(8;21) patient 
samples (supplemental Table 2), and the average expression level of FOXO1-activated genes was 
significantly higher in t(8;21) AML compared to other subtypes of AML (Figure 5C-D and supplemental 
Figure 3). Therefore, upregulation of the FOXO1 driven gene regulatory network was retained as a 
molecular feature in the acute leukemia stage of AE AML.  
FOXO1 and AE share genome-wide localization and FOXO1 maintains activation of key AE target 
genes 
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To identify the genomic targets of FOXO1 and AE we performed ChIP-Seq analysis in AE pre-leukemia 
cells. In total, 14723 AE- and 11835 FOXO1-bound loci were identified. Peak distributions differed 
slightly, with FOXO1 showing a greater localization to promoter regions than AE (Figure 6A). In 
agreement with our previous report showing FOXO binding motif enrichment in AE bound loci mapped 
in Kasumi-1 cells,21 we found 61% of AE and 76% of FOXO1 bound loci were in common (Figure 6B). 
Unbiased motif enrichment analysis of joint peaks showed that both RUNX1 and FOXO motifs were 
significantly enriched, together with ERG/ETS and E-Box motifs, consistent with our previous report 
(Figures 6C-D).21 Taken together, these results suggest that the FOXO1 and AE molecular networks are 
broadly interconnected.  
Cross analysis with RNA-seq data showed that about 50% of AE-regulated genes have both AE and 
FOXO1 bound in close proximity to the gene body (Figure 6E). The shared binding of AE and FOXO1 at 
several target genes was validated in t(8;21) cell lines as well (supplemental Figure 4A). The genome-
wide overlap of FOXO1 and AE binding sites compelled us to test whether FOXO1 was required for AE 
binding to its loci. Although we could detect a weak interaction between FOXO1 and AE in AE cells 
(supplemental Figure 4B), knockdown of FOXO1 did not affect the target binding of AE (supplemental 
Figure 4C), suggesting that the shared localization of the two proteins in chromatin does not require 
physical interaction. We identified MPL, UBASH3B and SOX4 as genomic targets for both AE and 
FOXO1. It has been reported that AE leukemic and pre-leukemic cells depend on MPL and UBASH3B 
for self-renewal and long-term proliferation.26-28 In addition, SOX4 is an AML oncogene which can 
efficiently transform mouse HSPCs.29 Histone H3 lysine 9 acetylation (H3K9Ac) and lysine 27 
acetylation (H3K27Ac) are epigenetic markers associated with active promoters and enhancers.30,31 The 
AE and FOXO1 binding peaks at these gene loci overlapped with our own published H3K9Ac enriched 
regions in Kasumi-1 cells as well as with H3K27Ac enriched regions identified in the ENCODE 
database,23,30 suggesting that AE and FOXO1 bind at bona fide gene regulatory elements (Figure 6F). 
Interestingly, FOXO1 knockdown in AE cells led to the down-regulation of all three genes (Figure 6G), 
which may account for the impaired growth of AE cells. Similar results were observed when FOXO1 was 
depleted in Kasumi-1 cells, although MPL was barely expressed in these cells, possibly due to them being 
cytokine-independent and not relying on MPL signaling (supplemental Figure 4D). These data suggest 
that the activation of a substantial set of AE targets and pre-leukemic stem cell programming cannot be 
fulfilled by AE itself and requires the up-regulation of FOXO1.  
Discussion 
Understanding the mechanisms through which leukemic oncogenes reprogram transcriptional networks 
and lead to enhanced self-renewal is an important prerequisite for efforts to specifically target leukemic 
and pre-leukemic stem cells and thus preventing relapse. The key mediators for leukemic programming of 
several subtypes of AML have been identified, including HOXA9/MEIS1 for MLL-translocation related 
AML, SOX4 for AML associated with CEBPA mutations and GATA2 for t(3;11) leukemia.29,32,33 Yet 
how AE promotes self-renewal and whether a key mediator exists in t(8;21) AML has been less clear. In 
this study, we identified FOXO1 as a critical regulator of the self-renewal program in AE pre-leukemia 
cells that is necessary and sufficient to initiate a pre-leukemic phenotype. We show that FOXO1 is 
required for full activation of a set of self-renewal genes and the long-term proliferation and clonogenicity 
of AE cells.  Importantly, enforced expression of FOXO1 in normal CD34+ HSPCs can partially 
recapitulate the cellular phenotype and gene signature of AE cells, revealing increased FOXO1 activity as 
a new molecular mechanism by which pre-leukemia stem cells establish an aberrant self-renewal program.  
FOXOs have complex functions and their role in leukemia is still unclear. In AML, it has been well 
documented that FOXO3 acts as tumor suppressor. It was shown that active IkappaB kinase sustains 
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AML proliferation by phosphorylating FOXO3 and thus preventing its nuclear entry, conversely, 
restoring nuclear localization of FOXO3 impaired AML cell growth.16 Similarly, it was demonstrated that 
FLT3-ITD, one frequent mutant in AML associated with poor disease outcome can promote FOXO3 
phosphorylation and thus preventing FOXO3-mediated apoptosis induction.34 Accordingly, a study of 511 
patients showed that high levels of phosphorylated FOXO3 indicating low FOXO3 activity was an 
independent adverse prognostic factor in AML.35 In addition, FOXO3 was shown to localize in the 
cytoplasm in PML-RARα-expressing AML cells and becoming activated during all-trans retinoic acid 
(ATRA) treatment. Knockdown of FOXO3 blocked ATRA-induced granulocytic differentiation and 
apoptosis.36 In contrast, FOXO3 was found to be important for maintaining AML stem cells in a mouse 
MLL-AF9 AML model. FOXO3 localized to the nucleus of AML stem cells, and depletion of FOXO3 
promoted myeloid differentiation and cell death, leading to a reduction of AML stem cell frequency.18 
However, the molecular mechanism by which FOXO3 is required for AML stem cells was not defined, 
and it is therefore unclear whether FOXO3 preserves leukemia stem cell activity by coordinating 
metabolic balance, similar to its role in normal HSC. In the current study, we show that FOXOs can also 
act as oncogenic factors and actively transform normal human HSPCs cells to AML upon increased 
expression, highlighting a new functional aspect of FOXOs in AML. Mechanistically, our data suggest 
that the oncogenic function of FOXO1 in AML is through the activation of a HSC program, which is 
critical for AE mediated pre-leukemia stem cell programming.  
Upregulation of FOXO1 is not restricted to t(8;21) AML.	 Interestingly, the FOXO1 core signature is also 
relatively enriched in inv(16) AML, correlating with high expression of FOXO1 in these samples (Figures 
5C-D, supplemental Figure 1A and supplemental Figure 3). inv(16) mutations disrupt the CBFB gene, 
generating the CBFB-MYH11 fusion. CBFB interacts with AML1 (RUNX1) to form the core binding 
factor (CBF) transcription complex, a critical regulator for normal hematopoiesis.37 In addition, FOXO1 
upregulation was also revealed in cytogenetically normal AML with AML1 mutations.38 It is therefore 
possible that FOXO1 is important for AML with CBF gene related mutations in general, and could play a 
more wide-spread role in development of other subtypes of AML as well. 
By virtue of selecting and regulating a set of AE target genes, FOXO1 reinforces the AE molecular 
network. Our analysis showed that target binding of AE did not depend on FOXO1. Together with the 
fact that increased FOXO1 was sufficient to elicit part of the AE gene signature in the absence of AE, this 
suggests that the genomic binding of FOXO1 and AE are independent. It is possible the genomic 
arrangement of binding motifs could serve as the basis for the coordination of AE and FOXO1. A 
significant number of genes across the genome have adjacent FOXO and RUNX binding motifs.39,40 It 
was also shown that FOXO1 and AML1 had functional interactions in breast cancer cell lines by jointly 
regulating a common set of genes.39 Since AE also recognizes RUNX motifs for chromatin binding, AE 
could hijack the network of FOXO1 and AML1 and thereby cooperate with FOXO1 for promoting a pre-
leukemia program. Alternatively, other co-binding factors may be involved in orchestrating the genomic 
binding of FOXO1 and AE. ETS transcription factors ERG and FLI1 have been reported to direct AE to 
specific binding regions.41 Genomic co-localization of ETS factors and FOXO in non-hematopoietic 
tissues has been suggested.42 As evidenced by our finding that ETS motifs were significantly enriched in 
FOXO1 bound loci, it is possible that ERG/FLI1 binding sites also demarcate targets for FOXO1, thus 
leading to the co-selection of targets by FOXO1 and AE.  
With the understanding that FOXOs are tumor suppressors, restoration of FOXO activity is being 
considered as a potential cancer therapy.15 Given the various functions of FOXOs in AML, caution has to 
be taken in applying this strategy until we fully understand the AML subtype specific role of FOXOs and 
evaluate the possible oncogenic effects on normal HSPCs. Considering the selective toxicity of the 
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FOXO1 inhibitor on AE pre-leukemic and leukemic cells, and the demonstration that an HSC defect was 
not seen in Foxo1-deleted mice,12 FOXO1 may be an effective therapeutic target for specifically 
eliminating malignant stem cells in AE and other FOXO1-overexpressing AMLs. 
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Figure legends 
Figure 1. FOXO1 is upregulated in AE leukemia and pre-leukemia cells.  
(A) Microarray analysis of FOXO1 transcript levels in t(8;21)-positive compared to t(8;21)-negative 
AML patient samples from Ross ME et al. (B) Immunoblot showing FOXO1 protein levels in t(8;21) and 
cytogenetically normal (non-t(8;21)) AML patient samples. (C and D) FOXO1 mRNA levels determined 
by qPCR (C, n=4, error bars represent SD) and protein levels (D) in AE- or empty vector (MIT)-
transduced CD34+ HSPCs. (E and F) Cellular fractionation immunoblot (E) and immunofluorescence 
analysis (F) to determine the subcellular localization of FOXO1 in AE cells. Scale bar=20 um. All p 
values were calculated by unpaired two-tailed t-test.   
Figure 2. Upregulation of FOXO1 depends on the presence of AE 
(A and B) qPCR and immunoblot analysis to determine FOXO1 mRNA (A, n=3, error bars represent SD) 
and protein (B) in AE-tet-off system following DOX addition. (C and D) RNA-seq analysis of FOXO1 
expression of Kasumi-1 cells transected with control siRNA (siMM) or AE siRNA (siAE). RNA-seq 
tracks (C) and relative FPKM values (D) are shown. n=3, error bars represent SD. p value was calculated 
by unpaired two-tailed t-test. (E) ChIP-seq analysis showed AE binding patterns at FOXO1 locus in 
Kasumi-1 cells. The sequence of the binding peak is shown with RUNX1 binding motifs highlighted. (F) 
ChIP-qPCR analysis of chromatin occupancy of AE (HA-tagged) at FOXO1 locus in AE cells, with 
primers indicated in (E) by arrow. RPL30 locus was used as negative control. n= 3, error bars represent 
SD. 
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Figure 3. FOXO1 inhibition impairs growth of AE cells.  
(A) AE cells were transduced with two sets of non-targeting shRNA (shNT) and FOXO1 shRNA (sh-1 
and sh-2) vectors that co-expressed Venus. Knockdown efficiency was confirmed by immunoblot. 
Growth of AE cells in liquid culture was measured as change of percentage of Venus+ cells relative to 
shNT by flow cytometry. One representative experiment of 3 replicates is shown. (B) CFU assay of sorted 
shRNA-transduced AE cells. n=3, results represent mean ± SD.*p<0.05, **p<0.01. (C) shRNA-
transduced AE cells were transplanted into immunodeficient mice. Venus+ percentage of human 
engrafted cells in bone marrow was examined 9 weeks later, and normalized to those before the 
transplantation. *p<0.005, **p<0.001. One representative experiment of 2 replicates is shown. (D) 
Survival curve of immunodeficient mice received fully transformed AE cells expressing shNT or FOXO1 
shRNA. Two independent experiments were included, p value was calculated by log-rank test. (E) CD34+ 
HSPCs and AE cells were treated with the FOXO1 inhibitor AS1842856 or DMSO, cell numbers were 
monitored over time. n=3, results represent mean ± SD. *p<0.01, paired two-tailed t-test. (F) Proliferation 
rate of cells treated with FOXO1 inhibitor at indicated concentration for 6 days, which is determined by 
WST-1 assay. Data are normalized to DMSO control (0 µM), and are shown as mean ± SD (n=3). IC50 
values for each type of cells are indicated.  (G-I) CFU assay of CD34+ HSPCs, AE cells (G), t(8;21) cell 
lines (H) and primary patient cells (I) treated with FOXO1 inhibitor. Data are normalized to DMSO-
treated cells (0 uM).  n=3, results represent mean ± SD. *p<0.05, **p<0.005. All p values were calculated 
by unpaired two-tailed t-test unless noted.   
Figure 4. Increased FOXO1 promotes a pre-leukemic state in human CD34+ HSPCs .   
(A) Weekly cell count of liquid culture of CD34+ HSPCs transduced with wildtype FOXO1 (WT), a 
FOXO1 mutant without a DNA binding domain (DB), or control (MIG) retroviral vectors. FOXO1 
expression was confirmed by immunoblot. One representative experiment of 3 replicates is shown. (B) 
Flow cytometry analysis of the myeloid differentiation marker CD11b on cells from a week 4 culture. (C) 
Wright-Giemsa staining of week 4 cultured cells. Scale bar=20 um. (D and E) CFU assay with transduced 
cells. Results represent mean ± SD of colony counts of first round (D, *p<0.05, **p<0.001) and second 
and third rounds (E, *p<0.01, **p<0.005), n=3. (F) Transduced cells were transplanted into 
immunodeficient mice. GFP+ percentage of human engrafted cells in bone marrow was examined 12 
weeks later, and normalized to those before the transplantation. *p<0.05, **p<1×10-5. One representative 
experiment of 2 replicates is shown. All p values were calculated by unpaired two-tailed t-test.   
Figure 5. FOXO1 gene signature is overrepresented in AE pre-leukemia and leukemia cells. 
(A) RNAseq analysis was performed on human CD34+ HSPCs transduced with indicated genes.  
Heatmap depicting hierarchical clustering of 1000 significantly differentially expressed genes of AE, 
FOXO1 WT and FOXO1 DB cells compared to MIG cells. The detailed gene list can be found in 
supplemental Table 1. (B) Pathway enrichment analysis of FOXO1-activating target genes showed 
enrichment of AE and HSC signatures. (C) Heatmap showing the expression level of FOXO1-activating 
gene signatures in different subtypes of AML patient samples. The dataset was from Ross ME et al. (D) 
Bean-plot depicting the average of the mean-centered log2 expression values of FOXO1-activating genes 
in different subtypes of AML patient samples. The dataset was from Ross ME et al. Black lines show the 
means of subgroups; each white line represents value of individual samples; polygons represent the 
estimated density of the data. p values were calculated by two-tailed t-test. 
Figure 6. FOXO1 regulates AE key target genes. 
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(A) Genomic location of AE and FOXO1 binding sites. (B) Venn diagram showing the overlap between 
AE and FOXO1 ChIP-seq peaks. (C) Enriched transcription factor binding motifs in jointly bound AE 
and FOXO1 ChIP-seq peaks. (D) Percentage of peaks containing predicted enriched motifs. (E) 
Percentage of AE-regulated genes associated with both AE and FOXO1 binding. (F) ChIP-seq tracks at 
SOX4, MPL and UBASH3B loci showing binding patterns of AE and FOXO1 in AE cells, H3K9Ac in 
Kasumi-1 cells, and layered H3K27Ac peaks of 7 cell lines from ENCODE.  Arrows indicate jointly 
bound AE and FOXO1 peaks. (G) Immunoblot to determine protein levels of MPL, UBASH3B and 
SOX4 upon FOXO1 knockdown in AE cells. 
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